메뉴 건너뛰기




Volumn 18, Issue 5, 2009, Pages 409-415

Therapeutic experience with acarbose in the treatment of type 2 diabetes

Author keywords

Acarbose; Body weight; HbA1c; Post prandial blood glucose; Type 2 diabetes

Indexed keywords

ACARBOSE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PLACEBO; REPAGLINIDE; SULFONYLUREA; VILDAGLIPTIN;

EID: 70349911614     PISSN: 18617603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (1)

References (60)
  • 1
    • 12644262888 scopus 로고
    • Pharmacology of alpha-glucosidase inhibitors
    • Vasselli J, Maggio C, Scriabine A (eds.): Neva Press, Branford, Connecticut
    • Bischoff H: Pharmacology of alpha-glucosidase inhibitors. In: Vasselli J, Maggio C, Scriabine A (eds.): Drugs in development: alpha-glucosidase inhibition: potential use in diabetes. Neva Press, Branford, Connecticut, 1993: 3-13
    • (1993) Drugs in Development: Alpha-glucosidase Inhibition: Potential Use in Diabetes , pp. 3-13
    • Bischoff, H.1
  • 3
    • 36749059401 scopus 로고    scopus 로고
    • Who should benefit from the use of alpha-glucosidase inhibitors?
    • Godbout A, Chiasson JL: Who should benefit from the use of alpha-glucosidase inhibitors? Curr Diab Rep 2007; 7: 333-339
    • (2007) Curr Diab Rep , vol.7 , pp. 333-339
    • Godbout, A.1    Chiasson, J.L.2
  • 4
    • 0017668659 scopus 로고
    • Glucosidase inhibition. A new approach to the treatment of diabetes, obesity, and hyperlipoproteinaemia
    • Puls W, Keup U, Krause HP, Thomas G, Hoffmeister F: Glucosidase inhibition. A new approach to the treatment of diabetes, obesity, and hyperlipoproteinaemia. Naturwissenschaften 1977; 64: 536-537
    • (1977) Naturwissenschaften , vol.64 , pp. 536-537
    • Puls, W.1    Keup, U.2    Krause, H.P.3    Thomas, G.4    Hoffmeister, F.5
  • 5
    • 0029147672 scopus 로고
    • Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose)
    • Qualmann C, Nauck MA, Holst JJ, Orskov C, Creutzfeldt W: Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose). Scand J Gastroenterol 1995; 30: 892-896
    • (1995) Scand J Gastroenterol , vol.30 , pp. 892-896
    • Qualmann, C.1    Nauck, M.A.2    Holst, J.J.3    Orskov, C.4    Creutzfeldt, W.5
  • 7
    • 40149101914 scopus 로고    scopus 로고
    • Acarbose: Oral anti-diabetes drug with additional cardiovascular benefits
    • Hanefeld M, Schaper F: Acarbose: oral anti-diabetes drug with additional cardiovascular benefits. Expert Rev Cardiovasc Ther 2008; 6: 153-163
    • (2008) Expert Rev Cardiovasc Ther , vol.6 , pp. 153-163
    • Hanefeld, M.1    Schaper, F.2
  • 8
    • 0028828123 scopus 로고
    • The effect of the timing and the administration of acarbose on postprandial hyperglycaemia
    • Rosak C, Nitzsche G, Konig P, Hofmann U: The effect of the timing and the administration of acarbose on postprandial hyperglycaemia. Diabet Med 1995; 12: 979-984
    • (1995) Diabet Med , vol.12 , pp. 979-984
    • Rosak, C.1    Nitzsche, G.2    Konig, P.3    Hofmann, U.4
  • 9
    • 0028798236 scopus 로고
    • Efficacy and tolerability of stepwise increasing dosage of acarbose in patients with non-insulin-dependent diabetes (NIDDM), treated with sulphonylureas
    • May C: Efficacy and tolerability of stepwise increasing dosage of acarbose in patients with non-insulin-dependent diabetes (NIDDM), treated with sulphonylureas. Diabetes und Stoffwechsel 1995; 4: 3-8
    • (1995) Diabetes und Stoffwechsel , vol.4 , pp. 3-8
    • May, C.1
  • 10
    • 0001891623 scopus 로고
    • Modulation of intestinal glucose absorption: Postponement of glucose absorption by alpha-glucosidase inhibitors
    • Mogensen CE, Standl E (eds.): de Gruyter, Berlin
    • Toeller M: Modulation of intestinal glucose absorption: postponement of glucose absorption by alpha-glucosidase inhibitors. In: Mogensen CE, Standl E (eds.): Pharmacology of diabetes. de Gruyter, Berlin, 1991
    • (1991) Pharmacology of Diabetes
    • Toeller, M.1
  • 11
    • 11844294865 scopus 로고    scopus 로고
    • Alpha-glucosidase inhibitors for patients with type 2 diabetes: Results from a Cochrane systematic review and meta-analysis
    • van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, Rutten GE, van Weel C: Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005; 28: 154-163
    • (2005) Diabetes Care , vol.28 , pp. 154-163
    • Van De Laar, F.A.1    Lucassen, P.L.2    Akkermans, R.P.3    Van De Lisdonk, E.H.4    Rutten, G.E.5    Van Weel, C.6
  • 12
    • 0031847292 scopus 로고    scopus 로고
    • An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet
    • Asian Acarbose Study Group
    • Chan JC, Chan KW, Ho LL, Fuh MM, Horn LC, Sheaves R, Panelo AA, Kim DK, Embong M: An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Asian Acarbose Study Group. Diabetes Care 1998; 21: 1058-1061
    • (1998) Diabetes Care , vol.21 , pp. 1058-1061
    • Chan, J.C.1    Chan, K.W.2    Ho, L.L.3    Fuh, M.M.4    Horn, L.C.5    Sheaves, R.6    Panelo, A.A.7    Kim, D.K.8    Embong, M.9
  • 13
    • 0029133235 scopus 로고
    • Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
    • Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE: Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 550-554
    • (1995) N Engl J Med , vol.333 , pp. 550-554
    • Stumvoll, M.1    Nurjhan, N.2    Perriello, G.3    Dailey, G.4    Gerich, J.E.5
  • 14
    • 0031762953 scopus 로고    scopus 로고
    • Metformin: A review of its metabolic effects
    • Cusi K, Defronzo R: Metformin: a review of its metabolic effects. Diab Rev 1998: 89-131 (Pubitemid 28554676)
    • (1998) Diabetes Reviews , vol.6 , Issue.2 , pp. 89-131
    • Cusi, K.1    Defronzo, R.A.2
  • 15
    • 0031460261 scopus 로고    scopus 로고
    • Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: The essen-II study
    • DOI 10.1016/S0002-9343(97)00252-0, PII S0002934397002520
    • Hoffmann J, Spengler M: Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study. Am J Med 1997; 103: 483-490 (Pubitemid 28018650)
    • (1997) American Journal of Medicine , vol.103 , Issue.6 , pp. 483-490
    • Hoffmann, J.1    Spengler, M.2
  • 16
    • 0027947449 scopus 로고
    • The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial
    • Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH, Wolever TM: The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 1994; 121: 928-935
    • (1994) Ann Intern Med , vol.121 , pp. 928-935
    • Chiasson, J.L.1    Josse, R.G.2    Hunt, J.A.3    Palmason, C.4    Rodger, N.W.5    Ross, S.A.6    Ryan, E.A.7    Tan, M.H.8    Wolever, T.M.9
  • 17
    • 0033884254 scopus 로고    scopus 로고
    • Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: A double-blind, placebo-controlled study
    • DOI 10.1016/S0168-8227(00)00163-7, PII S0168822700001637
    • Halimi S, Le Berre MA, Grange V: Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study. Diabetes Res Clin Pract 2000; 50: 49-56 (Pubitemid 30629019)
    • (2000) Diabetes Research and Clinical Practice , vol.50 , Issue.1 , pp. 49-56
    • Halimi, S.1    Le Berre, M.A.2    Grange, V.3
  • 20
    • 0012638922 scopus 로고    scopus 로고
    • Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin
    • DOI 10.2337/diacare.26.2.269
    • Phillips P, Karrasch J, Scott R, Wilson D, Moses R: Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin. Diabetes Care 2003; 26: 269-273 (Pubitemid 36929042)
    • (2003) Diabetes Care , vol.26 , Issue.2 , pp. 269-273
    • Phillips, P.1    Karrasch, J.2    Scott, R.3    Wilson, D.4    Moses, R.5
  • 21
    • 33748757957 scopus 로고    scopus 로고
    • Acarbose/metformin combination versus metformin alone in Indonesian patients with type 2 diabetes
    • Sumual AR, Pandelaki K, Rotty LAW: Acarbose/metformin combination versus metformin alone in Indonesian patients with type 2 diabetes. J Asean Fed Endocrine Soc 2003; 21: 24-31
    • (2003) J Asean Fed Endocrine Soc , vol.21 , pp. 24-31
    • Sumual, A.R.1    Pandelaki, K.2    Rotty, L.A.W.3
  • 22
    • 0033046464 scopus 로고    scopus 로고
    • A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)
    • DOI 10.2337/diacare.22.6.960
    • Holman RR, Cull CA, Turner RC: A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes Care 1999; 22: 960-964 (Pubitemid 29241052)
    • (1999) Diabetes Care , vol.22 , Issue.6 , pp. 960-964
    • Holman, R.R.1    Cull, C.A.2    Turner, R.C.3
  • 23
    • 0029658824 scopus 로고    scopus 로고
    • Mechanisms of the glycaemic effects of sulfonylureas
    • Ashcroft FM: Mechanisms of the glycaemic effects of sulfonylureas. Horm Metab Res 1996; 28: 456-463
    • (1996) Horm Metab Res , vol.28 , pp. 456-463
    • Ashcroft, F.M.1
  • 26
    • 0032885589 scopus 로고    scopus 로고
    • Comparison of acarbose and metformin in patients with Type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: A randomized, placebo-controlled study
    • DOI 10.1046/j.1464-5491.1999.00149.x
    • Willms B, Ruge D: Comparison of acarbose and metformin in patients with type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study. Diabet Med 1999; 16: 755-761 (Pubitemid 29459274)
    • (1999) Diabetic Medicine , vol.16 , Issue.9 , pp. 755-761
    • Willms, B.1    Ruge, D.2
  • 27
    • 0142105927 scopus 로고    scopus 로고
    • Long-Term Improvement of Metabolic Control by Acarbose in Type 2 Diabetes Patients Poorly Controlled with Maximum Sulfonylurea Therapy
    • DOI 10.2165/00044011-200323100-00007
    • Bachmann W, Petzinna D, Raptis SA, Wascher T, Westermeier T: Long-term improvement of metabolic control by acarbose in type 2 diabetes patients poorly controlled with maximum sulfonylurea therapy. Clin Drug Investig 2003; 23: 679-686 (Pubitemid 37289953)
    • (2003) Clinical Drug Investigation , vol.23 , Issue.10 , pp. 679-686
    • Bachmann, W.1    Petzinna, D.2    Raptis, S.A.3    Wascher, T.4    Westermeier, T.5
  • 28
    • 0030070954 scopus 로고    scopus 로고
    • A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients
    • Bayraktar M, Van Thiel DH, Adalar N: A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients. Diabetes Care 1996; 19: 252-254 (Pubitemid 26070353)
    • (1996) Diabetes Care , vol.19 , Issue.3 , pp. 252-254
    • Bayraktar, M.1    Van Thiel, D.H.2    Adalar, N.3
  • 29
    • 0028357199 scopus 로고
    • Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients: The essen study
    • Hoffmann J, Spengler M: Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study. Diabetes Care 1994; 17: 561-566 (Pubitemid 24161978)
    • (1994) Diabetes Care , vol.17 , Issue.6 , pp. 561-566
    • Hoffmann, J.1    Spengler, M.2
  • 30
    • 41749106662 scopus 로고    scopus 로고
    • Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: A 24-week, double-blind, randomized trial
    • Pan C, Yang W, Barona JP, Wang Y, Niggli M, Mohideen P, Foley JE: Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med 2008; 25: 435-441
    • (2008) Diabet Med , vol.25 , pp. 435-441
    • Pan, C.1    Yang, W.2    Barona, J.P.3    Wang, Y.4    Niggli, M.5    Mohideen, P.6    Foley, J.E.7
  • 31
    • 0035904785 scopus 로고    scopus 로고
    • Insulinotropic meglitinide analogues
    • Dornhorst A: Insulinotropic meglitinide analogues. Lancet 2001; 358: 1709-1716
    • (2001) Lancet , vol.358 , pp. 1709-1716
    • Dornhorst, A.1
  • 33
    • 4344630260 scopus 로고    scopus 로고
    • Modification of β-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application
    • Rosak C, Hofmann U, Paulwitz O: Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application. Diabetes Nutr Metab 2004; 17: 137-142 (Pubitemid 39117273)
    • (2004) Diabetes, Nutrition and Metabolism - Clinical and Experimental , vol.17 , Issue.3 , pp. 137-142
    • Rosak, C.1    Hofmann, U.2    Paulwitz, O.3
  • 34
    • 67649378996 scopus 로고    scopus 로고
    • Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: A double-blind, cross-over, clinical trial
    • Derosa G, Salvadeo SA, D'Angelo A, Ferrari I, Mereu R, Palumbo I, Maffioli P, Randazzo S, Cicero AF: Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial. Curr Med Res Opin 2009; 25: 607-615
    • (2009) Curr Med Res Opin , vol.25 , pp. 607-615
    • Derosa, G.1    Salvadeo, S.A.2    D'Angelo, A.3    Ferrari, I.4    Mereu, R.5    Palumbo, I.6    Maffioli, P.7    Randazzo, S.8    Cicero, A.F.9
  • 35
    • 33646538138 scopus 로고    scopus 로고
    • Impaired glucose tolerance, diabetes, and cardiovascular disease
    • Schnell O, Standl E: Impaired glucose tolerance, diabetes, and cardiovascular disease. Endocr Pract 2006; 12 (Suppl 1): 16-19 (Pubitemid 44963605)
    • (2006) Endocrine Practice , vol.12 , Issue.SUPPL. 1 , pp. 16-19
    • Schnell, O.1    Standl, E.2
  • 36
    • 0033139266 scopus 로고    scopus 로고
    • Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients
    • Guvener N, Gedik O: Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients. Acta Diabetol 1999; 36: 93-97
    • (1999) Acta Diabetol , vol.36 , pp. 93-97
    • Guvener, N.1    Gedik, O.2
  • 37
    • 0029032841 scopus 로고
    • A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes
    • Coniff RF, Shapiro JA, Seaton TB, Hoogwerf BJ, Hunt JA: A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes. Diabetes Care 1995; 18: 928-932
    • (1995) Diabetes Care , vol.18 , pp. 928-932
    • Coniff, R.F.1    Shapiro, J.A.2    Seaton, T.B.3    Hoogwerf, B.J.4    Hunt, J.A.5
  • 40
    • 0035986333 scopus 로고    scopus 로고
    • Acarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetic patients
    • Delgado H, Lehmann T, Bobbioni-Harsch E, Ybarra J, Golay A: Acarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetic patients. Diabetes Metab 2002; 28: 195-200 (Pubitemid 34746953)
    • (2002) Diabetes and Metabolism , vol.28 , Issue.3 , pp. 195-200
    • Delgado, H.1    Lehmann, T.2    Bobbioni-Harsch, E.3    Ybarra, J.4    Golay, A.5
  • 41
    • 0035030824 scopus 로고    scopus 로고
    • Safety and efficacy of acarbose in the treatment of type 2 diabetes: Data from a 5-year surveillance study
    • Mertes G: Safety and efficacy of acarbose in the treatment of type 2 diabetes: data from a 5-year surveillance study. Diabetes Res Clin Pract 2001; 52: 193-204
    • (2001) Diabetes Res Clin Pract , vol.52 , pp. 193-204
    • Mertes, G.1
  • 42
    • 0030870853 scopus 로고    scopus 로고
    • Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes
    • Wolever TMS, Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH: Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes. Nature 1997; 21: 756-763
    • (1997) Nature , vol.21 , pp. 756-763
    • Wolever, T.M.S.1    Chiasson, J.L.2    Josse, R.G.3    Hunt, J.A.4    Palmason, C.5    Rodger, N.W.6    Ross, S.A.7    Ryan, E.A.8    Tan, M.H.9
  • 43
    • 25644461255 scopus 로고    scopus 로고
    • Safety and tolerability of acarbose in the treatment of type 1 and type 2 diabetes mellitus
    • DOI 10.2165/00044011-200525090-00003
    • Neuser D, Benson A, Bruckner A, Goldberg RB, Hoogwerf BJ, Petzinna D: Safety and tolerability of acarbose in the treatment of type 1 and type 2 diabetes mellitus. Clin Drug Investig 2005; 25: 579-587 (Pubitemid 41379848)
    • (2005) Clinical Drug Investigation , vol.25 , Issue.9 , pp. 579-587
    • Neuser, D.1    Benson, A.2    Bruckner, A.3    Goldberg, R.B.4    Hoogwerf, B.J.5    Petzinna, D.6
  • 44
    • 25644435031 scopus 로고    scopus 로고
    • Long-term efficacy and tolerability of acarbose treatment in patients with type 2 diabetes mellitus
    • DOI 10.2165/00044011-200525090-00004
    • Segal P, Eliahou HE, Petzinna D, Neuser D, Bruckner A, Spengler M: Long-term efficacy and tolerability of acarbose treatment in patients with type 2 diabetes mellitus. Clin Drug Investig 2005; 25: 589-595 (Pubitemid 41379849)
    • (2005) Clinical Drug Investigation , vol.25 , Issue.9 , pp. 589-595
    • Segal, P.1    Eliahou, H.E.2    Petzinna, D.3    Neuser, D.4    Bruckner, A.5    Spengler, M.6
  • 45
    • 0031777678 scopus 로고    scopus 로고
    • The PROTECT Study: Final results of a large multicenter postmarketing study in patients with type 2 diabetes. Precose Resolution of Optimal Titration to Enhance Current Therapies
    • Buse J, Hart K, Minasi L: The PROTECT Study: final results of a large multicenter postmarketing study in patients with type 2 diabetes. Precose Resolution of Optimal Titration to Enhance Current Therapies. Clin Ther 1998; 20: 257-269
    • (1998) Clin Ther , vol.20 , pp. 257-269
    • Buse, J.1    Hart, K.2    Minasi, L.3
  • 46
    • 0029941276 scopus 로고    scopus 로고
    • An importance of carbohydrate ingestion for the expression of the effect of α-glucosidase inhibitor in NIDDM
    • Hara T, Nakamura J, Koh N, Sakakibara F, Takeuchi N, Hotta N: An importance of carbohydrate ingestion for the expression of the effect of alpha-glucosidase inhibitor in NIDDM. Diabetes Care 1996; 19: 642-647 (Pubitemid 26181114)
    • (1996) Diabetes Care , vol.19 , Issue.6 , pp. 642-647
    • Hara, T.1    Nakamura, J.2    Koh, N.3    Sakakibara, F.4    Takeuchi, N.5    Hotta, N.6
  • 47
    • 0036211095 scopus 로고    scopus 로고
    • Acarbose, an update of its therapeutic use in diabetes treatment
    • Laube H: Acarbose, an update of its therapeutic use in diabetes treatment. Clin Drug Investig 2002; 22: 141-156
    • (2002) Clin Drug Investig , vol.22 , pp. 141-156
    • Laube, H.1
  • 48
    • 0021854758 scopus 로고
    • Adaptation of the small intestine to induced maldigestion in rats. Experimental pancreatic atrophy and acarbose feeding
    • Creutzfeldt W, Folsch UR, Elsenhans B, Ballmann M, Conlon JM: Adaptation of the small intestine to induced maldigestion in rats. Experimental pancreatic atrophy and acarbose feeding. Scand J Gastroenterol 1985; 112 (Suppl): 45-53 (Pubitemid 15029602)
    • (1985) Scandinavian Journal of Gastroenterology, Supplement , vol.20 , Issue.SUPPL. 112 , pp. 45-53
    • Creutzfeldt, W.1    Folsch, U.R.2    Elsenhans, B.3
  • 49
    • 0000535567 scopus 로고
    • Influence of long-term intake of a glykosidehydrolaseinhibitor (BAY g 5421) on pancreatic exocrine secretion and contents of intestinal brush-border-enzymes
    • Folsch UR, van Schwamen E, Graf S, Caspary WF, Creutzfeldt W: Influence of long-term intake of a glykosidehydrolaseinhibitor (BAY g 5421) on pancreatic exocrine secretion and contents of intestinal brush-border-enzymes. Gastroent Clin Biol 1979; 3: 286-287
    • (1979) Gastroent Clin Biol , vol.3 , pp. 286-287
    • Folsch, U.R.1    Van Schwamen, E.2    Graf, S.3    Caspary, W.F.4    Creutzfeldt, W.5
  • 50
    • 0024343686 scopus 로고
    • Pharmacokinetics of acarbose. Part I: Absorption, concentration in plasma, metabolism and excretion after single administration of (14C) acarbose to rats, dogs and man
    • Ahr HJ, Boberg M, Krause HP, Maul W, Muller FO, Ploschke HJ, Weber H, Wunsche C: Pharmacokinetics of acarbose. Part I: Absorption, concentration in plasma, metabolism and excretion after single administration of (14C) acarbose to rats, dogs and man. Arzneimittelforschung 1989; 39: 1254-1260
    • (1989) Arzneimittelforschung , vol.39 , pp. 1254-1260
    • Ahr, H.J.1    Boberg, M.2    Krause, H.P.3    Maul, W.4    Muller, F.O.5    Ploschke, H.J.6    Weber, H.7    Wunsche, C.8
  • 51
    • 0024317398 scopus 로고
    • Pharmacokinetics of acarbose. Part II: Distribution to and elimination from tissues and organs following single or repeated administration of (14C)acarbose to rats and dogs
    • Ahr HJ, Krause HP, Siefert HM, Steinke W, Weber H: Pharmacokinetics of acarbose. Part II: Distribution to and elimination from tissues and organs following single or repeated administration of (14C)acarbose to rats and dogs. Arzneimittelforschung 1989; 39: 1261-1267
    • (1989) Arzneimittelforschung , vol.39 , pp. 1261-1267
    • Ahr, H.J.1    Krause, H.P.2    Siefert, H.M.3    Steinke, W.4    Weber, H.5
  • 52
    • 57149101128 scopus 로고    scopus 로고
    • The role of acarbose in type 2 diabetes combination therapy
    • Rosak C: The role of acarbose in type 2 diabetes combination therapy. Diabetes Stoffw Herz 2007; 16: 119-126
    • (2007) Diabetes Stoffw Herz , vol.16 , pp. 119-126
    • Rosak, C.1
  • 54
    • 24944497145 scopus 로고    scopus 로고
    • Evaluation of the efficacy and tolerability of acarbose in patients with diabetes mellitus a postmarketing surveillance study
    • DOI 10.2165/00044011-200525100-00004
    • Spengler M, Schmitz H, Landen H: Evaluation of the efficacy and tolerability of acarbose in patients with diabetes mellitus : a postmarketing surveillance study. Clin Drug Investig 2005; 25: 651-659 (Pubitemid 41330307)
    • (2005) Clinical Drug Investigation , vol.25 , Issue.10 , pp. 651-659
    • Spengler, M.1    Schmitz, H.2    Landen, H.3
  • 55
    • 33748784333 scopus 로고    scopus 로고
    • Postmarketing surveillance of acarbose treatment in Taiwanese patients with type 2 diabetes mellitus
    • DOI 10.2165/00044011-200626100-00002
    • Hung YJ, Kuo SW, Wang CH, Chang HY, Hsieh SH, Landen H: Postmarketing surveillance of acarbose treatment in Taiwanese patients with type 2 diabetes mellitus. Clin Drug Investig 2006; 26: 559-565 (Pubitemid 44411331)
    • (2006) Clinical Drug Investigation , vol.26 , Issue.10 , pp. 559-565
    • Hung, Y.-J.1    Kuo, S.-W.2    Wang, C.-H.3    Chang, H.-Y.4    Hsieh, S.-H.5    Landen, H.6
  • 56
    • 34249898882 scopus 로고    scopus 로고
    • Post-marketing surveillance of acarbose treatment in patients with type 2 diabetes mellitus and subjects with impaired glucose tolerance in China
    • DOI 10.2165/00044011-200727060-00003
    • Pan CY, Landen H: Post-marketing surveillance of acarbose treatment in patients with type 2 diabetes mellitus and subjects with impaired glucose tolerance in China. Clin Drug Investig 2007; 27: 397-405 (Pubitemid 46873101)
    • (2007) Clinical Drug Investigation , vol.27 , Issue.6 , pp. 397-405
    • Pan, C.-Y.1    Landen, H.2
  • 57
    • 42249106872 scopus 로고    scopus 로고
    • Efficacy, safety and acceptance of acarbose treatment under day-to-day practice conditions: A post-marketing surveillance of Chinese type 2 diabetic patients
    • Su SO, Zhao JJ, Zhang J, D.J. Z, Li H, Sheng ZY, Liang GX, Landen H: Efficacy, safety and acceptance of acarbose treatment under day-to-day practice conditions: a post-marketing surveillance of Chinese type 2 diabetic patients. Chin J Endocrinol Metab 2006; 22: a-1-a-5
    • (2006) Chin J Endocrinol Metab , vol.22
    • Su, S.O.1    Zhao, J.J.2    Zhang, J.D.J.Z.3    Li, H.4    Sheng, Z.Y.5    Liang, G.X.6    Landen, H.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.